Funding for this research was provided by:
Bristol-Myers Squibb Canada (N/A)
Ono Pharmaceutical (N/A)
Received: 25 August 2020
Accepted: 24 May 2021
First Online: 1 June 2021
: The study was approved by the Institutional Review Board of Nagasaki University (approval no. 13102866). All patients gave signed informed consent.
: Not applicable.
: AK has received research funding from Ono Pharmaceutical Co., Sanofi K.K., Asahi Kasei Pharma Corp., Taisho Toyama Pharmaceutical Co., Teijin Pharma Co., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., MSD Co., Kowa Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co., Pfizer Japan Inc., Kyowa Hakko Kirin Co., Boehringer Ingelheim Japan, Abbvie GK, Astellas Pharma Inc., Eli Lilly Japan, Daiichi Sankyo Co., Takeda Pharmaceutical Co., Kissei Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Cosmic Corporation Co. Ltd., Nihon Medi-Physics Co., Ltd., Daiichi Sankyo Co., Bristol-Myers Squibb, Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., AstraZeneca Co., YL Biologics Co., Alexion GK, and Eisai Co. The other authors declare that they have no competing interests.